Belimumab for systemic lupus erythematosus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Singh, Jasvinder A ^a   Noorbaloochi, Shahrzad ^b   Tucker, Matthew D ^c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB;

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; INTERVENTION STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 85038939261     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010668     Document Type: Article

References (23)

1. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Seminars in Immunology 2006;18(5):263-75.
2. Cates C. EBM Web Site. Visual Rx Version 3 (accessed October 2011) [Computer program]. Available from: www.nntonline.net/visualrx 2004.
3. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis and Rheumatism 2001;44:1313-9.
4. Collins CE, Gavin AL, Migone T-S, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Research and Therapy 2006;8:R6.
5. Crow M, Kirou KA. Interferon-alpha in systemic lupus erythematosus. Current Opinion in Rheumatology 2004;16:541-7.
6. Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP. Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Seminars in Immunology 2005;17(3):193-9.
7. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
8. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al.Novel evidence-based systemic lupus erythematosus responder index. Arthritis and Rheumatism 2009;61(9):1143-51.
9. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al.Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus. Journal of Rheumatology 1992;19(11):1820-1.
10. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al.The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Quarterly Journal of Medicine 1993;86(7):447-58.
11. Higgins JP, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and Rheumatism 1997;40(9):1725.
13. Isenberg DA, Gordon C. From BILAG to BLIPS - disease activity assessment in lupus past, present and future. Lupus 2000;9(9):651-4.
14. Kim WU, Sreih A, Bucala R. Toll-like receptors in systemic lupus erythematosus prospects for therapeutic intervention. Autoimmunity Reviews 2009;8:204-8.
15. Kim SS, Kirou KA, Erkan D. Belimumab in systemic lupus erythematosus: an update for clinicians. Therapeutic Advances in Chronic Disease 2012;3(1):11-23.
16. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al.DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunology 2002;3:822-9.
17. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clinical and Experimental Rheumatology 2006;24(6 Suppl 43):S99-104.
18. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8(8):685-91.
19. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al.Combined oral contraceptives in women with systemic lupus erythematosus. New England Journal of Medicine 2005;353(24):2550-8.
20. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B-lymphocyte stimulator (BLyS) levels and disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 2008;58:2453-9.
21. Ravirajan CT, Sarraf CE, Anilkumar TV, Golding MC, Alison MR, Isenberg D. An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic lupus erythematosus (SLE). Clinical and Experimental Immunology 1996;105:306-12.
22. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] . The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.